Clinical trial
A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in…
NCT00034476 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00034476 |
|---|---|
| Title | A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis |
| Official title | A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | sPLA2 Inhibitor |
| Enrollment | 466 |
| Start date | Oct 1, 2001 |
| Completion | Oct 1, 2002 |
| First posted | Apr 30, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | Belgium, Hungary, Netherlands, Poland, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: